According to Enzo Biochem's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.18085. At the end of 2022 the company had a P/E ratio of -2.60.
Year | P/E ratio | Change |
---|---|---|
2022 | -2.60 | -108.1% |
2021 | 32.1 | -647.74% |
2020 | -5.86 | -104.46% |
2019 | 132 | -1660.97% |
2018 | -8.42 | -96.95% |
2017 | -276 | -3482.81% |
2016 | 8.16 | -74.6% |
2015 | 32.1 | -280.98% |
2014 | -17.8 | 167.62% |
2013 | -6.64 | 143.33% |
2012 | -2.73 | -47.65% |
2011 | -5.21 | -43.76% |
2010 | -9.26 | -13.91% |
2009 | -10.8 | -5.38% |
2008 | -11.4 | -67.87% |
2007 | -35.4 | 6.64% |
2006 | -33.2 | -35.87% |
2005 | -51.8 | -105.32% |
2004 | 973 | -170.02% |
2003 | < -1000 | -3193.47% |
2002 | 44.9 | -51.43% |
2001 | 92.5 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Quest Diagnostics
DGX | 21.1 | -1,884.27% | ๐บ๐ธ USA |
LabCorp LH | 28.3 | -2,500.12% | ๐บ๐ธ USA |
RadNet RDNT | -250 | 21,100.66% | ๐บ๐ธ USA |
Psychemedics PMD | -7.51 | 535.56% | ๐บ๐ธ USA |
NeoGenomics
NEO | -16.3 | 1,279.81% | ๐บ๐ธ USA |
Qiagen QGEN | 31.6 | -2,778.23% | ๐ณ๐ฑ Netherlands |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.